#None #Milan #Hansoh Pharma #EASD 2026 #Olatorepatide

Significant Weight Loss with Olatorepatide at EASD 2026

From September 28 to October 2, 2026, Milan hosted the annual meeting of the European Association for the Study of Diabetes (EASD). During the event, Hansoh Pharma presented compelling data from its Phase III study of olatorepatide (HS-20094), a dual-function selective agonist for GLP-1 and GIP receptors, focusing on weight regulation among adults with obesity.

Efficacy and Safety Results

The presentation highlighted substantial efficacy, revealing an average weight loss of 19.3% by week 48 in the 15 mg olatorepatide group, without any observed plateau in weight loss. Moreover, the waist circumference in the same group decreased by an average of 16.0 cm. The reported adverse effects related to gastrointestinal issues included nausea at 7.8% and vomiting at 4.9%, showing a favorable safety profile.

The LIGHTEN study was a multicenter, randomized, double-blind, placebo-controlled Phase III trial involving 604 adult participants in China. Eligible individuals had a body mass index (BMI) of ≥28 kg/m² or BMI 24 – 28 kg/m² along with at least one weight-related comorbidity. Participants received weekly subcutaneous injections of olatorepatide (5 mg, 10 mg, or 15 mg) or placebo over a span of 48 weeks.

Key Findings

Weight Loss Metrics

The study's primary endpoints included the percentage change in body weight from baseline and the proportion of participants achieving a weight loss of ≥5% after 48 weeks. Data illustrated that participants in olatorepatide groups witnessed average weight reductions of -12.5%, -17.5%, and -19.3% for 5 mg, 10 mg, and 15 mg doses respectively, compared to -2.7% in the placebo group. Statistically significant differences were confirmed (P < 0.0001).

Participants' Success Rates

In terms of success rates, the percentages of participants reaching the defined weight loss milestones were impressive:

• - Weight loss ≥5%: 87.3%, 97.2%, and 95.2% for 5 mg, 10 mg, and 15 mg, respectively, versus 28.6% for placebo.
• - Weight loss ≥10%: 61.7%, 89.3%, 88.9% against 14.6% for placebo.
• - Weight loss ≥15%: 32.6%, 60.2%, and 71.7% compared to 3.2% for placebo.

Waist Circumference and Metabolic Benefits

The average reduction in waist circumference was 10.5 cm, 14.4 cm, and 16.0 cm for the respective olatorepatide doses, contrasting with 3.6 cm in the placebo arm. Furthermore, olatorepatide significantly improved various metabolic parameters such as blood pressure, lipid profiles, HbA1c, HOMA-IR, urinary albumin-to-creatinine ratio, and uric acid levels, underscoring its comprehensive metabolic benefits.

The overall safety profile of olatorepatide was consistent with existing treatments targeting weight management based on incretin hormones, demonstrating a lower incidence of gastrointestinal side effects compared to published data on currently available drugs in the same category.

Conclusion

Olatorepatide represents a novel approach to tackling the challenges of achieving effective and tolerable weight loss. The LIGHTEN study's results suggest significant weight reduction efficacy alongside a favorable safety and tolerability profile, positioning olatorepatide as a promising new therapeutic option for weight management.

The annual EASD meeting is noted for being a leading academic conference in the fields of diabetes and metabolism worldwide, pointing to the high recognition of the clinical importance and quality data presented at this event.

Olatorepatide is administered as a subcutaneous injection once weekly, operating through the modulation of metabolic pathways that govern appetite control, glucose metabolism, and energy balance. It is currently also undergoing Phase III clinical trials in China for the treatment of type 2 diabetes mellitus, with Hansoh Pharmaceutical having partnered with Regeneron to develop and commercialize the drug internationally.

Hansoh Pharma remains a pivotal player in China's pharmaceutical sector, driven by its commitment to innovation aimed at enhancing lives through ongoing advancements.